Express News | Wuhan Keqian Biology Co.,Ltd: Obtained the veterinary drug GMP certificate and veterinary drug production license.

BreakingsDec 31, 2024 16:34

China Galaxy Securities 2025 Annual Strategy for the Agriculture, Forestry, Animal Husbandry, and Fishery Industry: Focusing on the Breeding Industry Chain, Looking Forward to Efficiency and Growth.

To further boost the growth Sector, investment opportunities in Agriculture in 2025 can still revolve around the breeding Industry Chain.

Zhitong FinanceDec 26, 2024 17:06

Wuhan Keqian Biology Co., Ltd (688526.SH): Plans to sign a cooperative research and development agreement with Huazhong Agricultural University.

On December 9th, Gelonghui reported that wuhan keqian biology co.,ltd (688526.SH) announced that in order to enhance the company's market competitiveness and accelerate the development in the biological product industry, thereby better enhancing the company's brand influence and core competitiveness, according to the "Articles of Association," "Cooperative Research and Development Management System," and other regulations, after competitive negotiations with Huazhong Agricultural University, the company has obtained a trivalent inactivated vaccine for chicken infectious rhinitis (Type A + Type B + Type C, recombinant protein), chicken Mycoplasma synoviae, chicken Mycoplasma gallisepticum (HB03 strain + HB15 strain), recombinant Newcastle disease virus, infectious bronchitis virus, and bird flu virus (H9 subtype), and infectious law.

Gelonghui FinanceDec 9, 2024 15:57

wuhan keqian biology co.,ltd (688526): Revenue improved compared to the previous month, aquaculture warming up, performance expected to grow.

Performance summary: The company released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.666 billion yuan, a year-on-year decrease of -19.57%, and achieved a net income attributable to shareholders of 0.261 billion yuan, a year-on-year decrease of -27.09%; after deducting non-recurring items.

西南证券Nov 5, 2024 00:00

wuhan keqian biology co.,ltd (688526.SH): has repurchased 0.4296% of the shares accumulated.

On November 4th, Keqian Biology (688526.SH) announced that as of October 31, 2024, the company has repurchased a total of 2,002,347 shares through the Shanghai Stock Exchange trading system by means of centralized competitive bidding, accounting for 0.4296% of the total share capital of 466,128,056 shares. The highest repurchase price was 18.90 yuan/share, the lowest price was 13.29 yuan/share, and the total amount paid was RMB 32,945,273.72 yuan (excluding stamp duty, transaction commission, and other transaction costs).

Gelonghui FinanceNov 4, 2024 15:45

wuhan keqian biology co.,ltd (688526): Profitability improves month-on-month, waiting patiently for the recovery of performance in the later cycle.

Event: In the first three quarters of 2024, the company's revenue decreased by 19.57%, and net income attributable to shareholders decreased by 27.09%. In the first half of 2024, the company achieved revenue of 0.666 billion yuan (a decrease of 19.57% year-on-year) and net income attributable to shareholders of 2.6 billion yuan.

caitong securitiesOct 31, 2024 16:28